8-KLeadership ChangesRegulation FDExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (Sep 10, 2026)

Filed September 10, 2026For Securities:DXCM

Summary

DexCom, Inc. (DXCM) announced a strategic expansion of its Board of Directors on September 10, 2026, by increasing its size to thirteen members and appointing Glenn S. Boehnlein as a new independent director. This move is designed to enhance the Board's expertise and oversight as the company continues its growth trajectory in the continuous glucose monitoring market. Mr. Boehnlein's appointment is effective immediately and he will serve until the 2027 annual meeting of stockholders. He has been assigned to key committees, including the Operations & Innovation Committee and the Audit Committee, indicating a focus on strategic development and financial governance. His compensation includes a significant initial equity grant of $500,000 in restricted stock units (RSUs) vesting over three years, plus an annual RSU grant of $347,500, aligning his interests with long-term shareholder value. This appointment signals DexCom's commitment to robust corporate governance and operational excellence.

Key Highlights

  • 1DexCom, Inc. expanded its Board of Directors to thirteen members.
  • 2Glenn S. Boehnlein was appointed as a new independent director.
  • 3Mr. Boehnlein's term will expire at the 2027 annual stockholder meeting.
  • 4He has been appointed to the Operations & Innovation Committee and the Audit Committee.
  • 5Mr. Boehnlein received an initial equity grant of $500,000 in RSUs, vesting over three years.
  • 6He is eligible for an annual equity grant valued at $347,500.
  • 7The appointment and associated compensation are designed to align director interests with long-term shareholder value.

Frequently Asked Questions

Glenn S. Boehnlein has been appointed as a new independent director to DexCom's Board. While the filing does not detail his specific professional background, his appointment to key committees like Operations & Innovation and Audit suggests a focus on leveraging his expertise in strategic growth and financial oversight for the company.

Mr. Boehnlein's compensation includes an initial appointment equity grant of $500,000 in restricted stock units (RSUs) that vest annually over three years. He will also receive an annual RSU grant valued at $347,500, with vesting typically occurring on the first anniversary of the grant or at the next annual stockholder meeting, provided he remains in service. Vesting is accelerated upon a change in control.

No, the filing explicitly states that there is no arrangement or understanding between Mr. Boehnlein and any other person regarding his selection, and he does not have any direct or indirect material interest in any transaction that requires disclosure under Item 404(a) of Regulation S-K. The Board has determined he is an independent director.

Increasing the Board size from twelve to thirteen directors allows DexCom to add new expertise and perspectives. The appointment of Mr. Boehnlein to strategic committees like Operations & Innovation and Audit indicates a focus on strengthening governance and driving future growth initiatives within the company.